

William R Hiatt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1231212/publications.pdf>

Version: 2024-02-01

104
papers

6,665
citations

101543

36
h-index

62596

80
g-index

104
all docs

104
docs citations

104
times ranked

7419
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical Update: Cardiovascular Disease in Diabetes Mellitus. <i>Circulation</i> , 2016, 133, 2459-2502.	1.6	766
2	Rivaroxaban in Peripheral Artery Disease after Revascularization. <i>New England Journal of Medicine</i> , 2020, 382, 1994-2004.	27.0	566
3	Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. <i>New England Journal of Medicine</i> , 2017, 376, 32-40.	27.0	494
4	Effect of Diagnostic Criteria on the Prevalence of Peripheral Arterial Disease. <i>Circulation</i> , 1995, 91, 1472-1479.	1.6	441
5	Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. <i>Journal of Vascular Surgery</i> , 2014, 60, 686-695.e2.	1.1	346
6	Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. <i>American Heart Journal</i> , 2018, 206, 80-93.	2.7	276
7	Evaluation and Treatment of Patients With Lower Extremity Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2015, 65, 931-941.	2.8	269
8	Intensive Blood Pressure Control Reduces the Risk of Cardiovascular Events in Patients With Peripheral Arterial Disease and Type 2 Diabetes. <i>Circulation</i> , 2003, 107, 753-756.	1.6	216
9	Cardiovascular Drug Development. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1567-1582.	2.8	168
10	The Cardiovascular Safety of Diabetes Drugs – Insights from the Rosiglitazone Experience. <i>New England Journal of Medicine</i> , 2013, 369, 1285-1287.	27.0	163
11	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries. <i>Journal of Endovascular Therapy</i> , 2015, 22, 663-677.	1.5	152
12	Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1338-1357.	2.8	144
13	A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization. <i>Circulation</i> , 2017, 135, 2534-2555.	1.6	136
14	Pathogenesis of the Limb Manifestations and Exercise Limitations in Peripheral Artery Disease. <i>Circulation Research</i> , 2015, 116, 1527-1539.	4.5	128
15	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). <i>Vascular Medicine</i> , 2015, 20, 465-478.	1.5	127
16	An Update on Methods for Revascularization and Expansion of the TASC Lesion Classification to Include Below-the-Knee Arteries: A Supplement to the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). <i>Annals of Vascular Diseases</i> , 2015, 8, 343-357.	0.5	122
17	Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. <i>Circulation</i> , 2017, 135, 241-250.	1.6	111
18	Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). <i>American Heart Journal</i> , 2018, 199, 83-91.	2.7	104

#	ARTICLE	IF	CITATIONS
19	Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program. <i>Diabetologia</i> , 2019, 62, 926-938.	6.3	94
20	Oxygen uptake kinetics during exercise are slowed in patients with peripheral arterial disease. <i>Journal of Applied Physiology</i> , 1999, 87, 809-816.	2.5	82
21	Acute Limb Ischemia in Peripheral Artery Disease. <i>Circulation</i> , 2019, 140, 556-565.	1.6	80
22	An update on methods for revascularization and expansion of the TASC lesion classification to include below-the-knee arteries: A supplement to the inter-society consensus for the management of peripheral arterial disease (TASC II): The TASC steering committee*. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 611-625.	1.7	76
23	Major Adverse Limb Events and 1-Year Outcomes After Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2018, 72, 999-1011.	2.8	76
24	Pharmacologic therapy for peripheral arterial disease and claudication. <i>Journal of Vascular Surgery</i> , 2002, 36, 1283-1291.	1.1	73
25	Effect of intravenous L-carnitine on carnitine homeostasis and fuel metabolism during exercise in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 55, 681-692.	4.7	69
26	Cardiovascular and Limb Outcomes in Patients With Diabetes and Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 3274-3284.	2.8	64
27	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. <i>Circulation</i> , 2020, 142, 2219-2230.	1.6	58
28	Long-Term Outcomes and Associations With Major Adverse Limb Events After Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2020, 75, 498-508.	2.8	57
29	Evaluating the Cardiovascular Safety of New Medications for Type 2 Diabetes: Time to Reassess?. <i>Diabetes Care</i> , 2016, 39, 738-742.	8.6	52
30	Statins and Major Adverse Limb Events in Patients with Peripheral Artery Disease: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 866-875.	3.4	52
31	Carnitine and Peripheral Arterial Disease. <i>Annals of the New York Academy of Sciences</i> , 2004, 1033, 92-98.	3.8	51
32	Post-Discharge Prophylaxis With Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. <i>Journal of the American College of Cardiology</i> , 2020, 75, 3140-3147.	2.8	50
33	Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. <i>American Heart Journal</i> , 2016, 175, 86-93.	2.7	41
34	Clinical Trials in Peripheral Vascular Disease. <i>Circulation</i> , 2014, 130, 1812-1819.	1.6	40
35	Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease. <i>Vascular Medicine</i> , 2014, 19, 473-482.	1.5	39
36	Community-based walking exercise for peripheral artery disease: An exploratory pilot study. <i>Vascular Medicine</i> , 2015, 20, 339-347.	1.5	39

#	ARTICLE	IF	CITATIONS
37	Cardiovascular Outcomes After Lower-Extremity Endovascular or Surgical Revascularization. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1563-1572.	2.8	39
38	Inflammatory Cytokines Associated With Failure of Lower-Extremity Endovascular Revascularization (LER): A Prospective Study of a Population With Diabetes. <i>Diabetes Care</i> , 2019, 42, 1939-1945.	8.6	38
39	Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization and death in outpatients with COVID-19: The PREVENT-HD study. <i>American Heart Journal</i> , 2021, 235, 12-23.	2.7	36
40	Stroke in Patients With Peripheral Artery Disease. <i>Stroke</i> , 2019, 50, 1356-1363.	2.0	33
41	Contemporary Trends in Hospital Admissions and Outcomes in Patients With Critical Limb Ischemia. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e007539.	2.2	33
42	Beta-2 adrenergic blockade evaluated with epinephrine after placebo, atenolol, and nadolol. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 2-6.	4.7	31
43	Effect of Propionyl-L-carnitine on a Background of Monitored Exercise in Patients With Claudication Secondary to Peripheral Artery Disease. <i>Journal of Cardiopulmonary Rehabilitation and Prevention</i> , 2011, 31, 125-132.	2.1	31
44	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. <i>Journal of the American College of Cardiology</i> , 2021, 78, 317-326.	2.8	30
45	Age does not alter human vascular and nonvascular β_2 -adrenergic responses to isoproterenol. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 573-578.	4.7	28
46	Outcomes of Patients with Critical Limb Ischaemia in the EUCLID Trial. <i>European Journal of Vascular and Endovascular Surgery</i> , 2018, 55, 109-117.	1.5	28
47	Urinary 11-dehydro-thromboxane B2 is associated with cardiovascular events and mortality in patients with atrial fibrillation. <i>American Heart Journal</i> , 2015, 170, 490-497.e1.	2.7	26
48	Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease. <i>JAMA Cardiology</i> , 2019, 4, 7.	6.1	26
49	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. <i>Circulation</i> , 2021, 144, 1104-1116.	1.6	25
50	Rationale and Design for PACE: Patients with Intermittent Claudication Injected with ALDH Bright Cells. <i>American Heart Journal</i> , 2014, 168, 667-673.e2.	2.7	24
51	Masterclass series in peripheral arterial disease. <i>Vascular Medicine</i> , 2006, 11, 55-60.	1.5	23
52	Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 3016-3027.	2.8	23
53	Short-Term Effects of Estrogen and Progestin on Blood Pressure of Normotensive Postmenopausal Women. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 543-548.	2.0	21
54	Cardiovascular Safety Outcome Trials: A meeting report from the Cardiac Safety Research Consortium. <i>American Heart Journal</i> , 2015, 169, 486-495.	2.7	21

#	ARTICLE	IF	CITATIONS
55	Quality of the assessment of primary and secondary endpoints in claudication and critical leg ischemia trials. <i>Vascular Medicine</i> , 2005, 10, 207-213.	1.5	20
56	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1768-1778.	2.8	19
57	Selective and nonselective β^2 -blockade of the peripheral circulation. <i>Clinical Pharmacology and Therapeutics</i> , 1984, 35, 12-18.	4.7	18
58	The Treatment Gap in Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2301-2303.	2.8	17
59	Randomized trial of AT-1015 for treatment of intermittent claudication. A novel 5-hydroxytryptamine antagonist with no evidence of efficacy. <i>Vascular Medicine</i> , 2004, 9, 18-25.	1.5	16
60	Association of Hypertension and Arterial Blood Pressure on Limb and Cardiovascular Outcomes in Symptomatic Peripheral Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006512.	2.2	16
61	A validated biomarker panel to identify peripheral artery disease. <i>Vascular Medicine</i> , 2012, 17, 386-393.	1.5	14
62	The effect of inhibition of acyl coenzyme A-cholesterol acyltransferase (ACAT) on exercise performance in patients with peripheral arterial disease. <i>Vascular Medicine</i> , 2004, 9, 271-277.	1.5	13
63	New Drug Application 21-628, Certican (Everolimus), for the Proposed Indication of Prophylaxis of Rejection in Heart Transplantation. <i>Circulation</i> , 2006, 113, e394-5.	1.6	13
64	Cardiovascular Risk Assessment in the Development of New Drugs for Obesity. <i>JAMA - Journal of the American Medical Association</i> , 2012, 308, 1099.	7.4	13
65	Prioritization of treatments for lower extremity peripheral artery disease in low- and middle-income countries. <i>International Angiology</i> , 2017, 36, 203-215.	0.9	13
66	Chronic kidney disease and risk for cardiovascular and limb outcomes in patients with symptomatic peripheral artery disease: The EUCLID trial. <i>Vascular Medicine</i> , 2019, 24, 422-430.	1.5	13
67	Exercise Training and Revascularization in the Management of Symptomatic Peripheral Artery Disease. <i>JACC Basic To Translational Science</i> , 2021, 6, 174-188.	4.1	13
68	Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. <i>Journal of the American Heart Association</i> , 2021, 10, e018684.	3.7	13
69	Acute Pharmacological Conversion of Atrial Fibrillation to Sinus Rhythm. <i>Circulation</i> , 2008, 117, 2956-2957.	1.6	12
70	Assessing the Clinical Benefits of Lipid-Disorder Drugs. <i>New England Journal of Medicine</i> , 2014, 370, 396-399.	27.0	12
71	Effect of tirasemtiv, a selective activator of the fast skeletal muscle troponin complex, in patients with peripheral artery disease. <i>Vascular Medicine</i> , 2014, 19, 297-306.	1.5	8
72	Association of Disease Progression With Cardiovascular and Limb Outcomes in Patients With Peripheral Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009326.	3.9	7

#	ARTICLE	IF	CITATIONS
73	Association of Health Status Scores With Cardiovascular and Limb Outcomes in Patients With Symptomatic Peripheral Artery Disease: Insights From the EUCLID (Examining Use of Ticagrelor in) Tj ETQq1 1 0.784314 rgBT ₇ /Overlook e016573.	3.7	7
74	Impact of Procedural Bleeding in Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2019, 12, e008069.	3.9	6
75	Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID Trial. International Journal of COPD, 2021, Volume 16, 841-851.	2.3	6
76	Association of Bleeding Severity With Mortality in Extended Thromboprophylaxis of Medically Ill Patients in the MAGELLAN and MARINER Trials. Circulation, 2022, 145, 1471-1479.	1.6	6
77	The Society for Vascular Medicine: The first quarter century. Vascular Medicine, 2015, 20, 60-68.	1.5	5
78	Guideline-directed statin intensification in patients with new or worsening symptoms of peripheral artery disease. Clinical Cardiology, 2018, 41, 1414-1422.	1.8	5
79	Healthcare resource utilization and costs of major atherothrombotic vascular events among patients with peripheral artery disease after revascularization. Journal of Medical Economics, 2021, 24, 402-409.	2.1	5
80	Incidence of Major Atherothrombotic Vascular Events among Patients with Peripheral Artery Disease after Revascularization. Annals of Vascular Surgery, 2021, 75, 217-226.	0.9	5
81	Lost in translation: Why "lost to follow-up" matters. Vascular Medicine, 2019, 24, 339-340.	1.5	4
82	Rivaroxaban for extended thromboprophylaxis in acutely ill medical patients 75 years of age or older. Journal of Thrombosis and Haemostasis, 2021, 19, 2772-2780.	3.8	4
83	The Kids-DOTT Trial: Novel Aspects of the "Parallel Cohort RCT" Design and Its Application to the Investigation of Duration of Anticoagulant Therapy for Pediatric Venous Thromboembolism.. Blood, 2009, 114, 4169-4169.	1.4	4
84	From the Masters: A sea-change for TransAtlantic Inter-Society Consensus (TASC). Vascular Medicine, 2020, 25, 103-105.	1.5	3
85	Progress in the prevention and treatment of atherosclerotic cardiovascular disease: two steps forward, one step back. European Heart Journal, 2020, 41, 1650-1652.	2.2	3
86	Ankle-Brachial Index for Risk Stratification in Patients With Symptomatic Peripheral Artery Disease With and Without Prior Lower Extremity Revascularization: Observations From the EUCLID Trial. Circulation: Cardiovascular Interventions, 2021, 14, e009871.	3.9	2
87	Etiology and outcomes of amputation in patients with peripheral artery disease in the EUCLID trial. Journal of Vascular Surgery, 2022, 75, 660-670.e3.	1.1	2
88	World regional differences in outcomes for patients with peripheral artery disease: Insights from the EUCLID trial. Vascular Medicine, 2021, , 1358863X2110386.	1.5	2
89	The Effect of Platelet Protein and Dna on the Measurement of Human Lymphocyte Beta Adrenergic Receptor Number. Journal of Receptors and Signal Transduction, 1985, 5, 419-429.	1.2	1
90	Heart Failure and Peripheral Artery Disease. JACC: Heart Failure, 2014, 2, 455-456.	4.1	1

#	ARTICLE	IF	CITATIONS
91	The Development of Therapeutics for Peripheral Artery Disease. Journal of the American College of Cardiology, 2016, 67, 2729-2731.	2.8	1
92	Ticagrelor in Peripheral Artery Disease Endovascular Revascularization (TI-PAD): Challenges in clinical trial execution. Vascular Medicine, 2018, 23, 513-522.	1.5	1
93	Heterogeneity of Risk and Benefit in Subgroups of COMPASS. Journal of the American College of Cardiology, 2019, 73, 3292-3294.	2.8	1
94	Plantar Flexion-Induced Entrapment of the Dorsalis Pedis Artery in a Teenaged Cross-Country Runner. Annals of Vascular Surgery, 2021, 70, 213-218.	0.9	1
95	Abciximab added to urokinase increased amputation-free survival in peripheral arterial occlusion of the legs. ACP Journal Club, 2002, 137, 12.	0.1	1
96	Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. TH Open, 2022, 06, e177-e183.	1.4	1
97	Propionyl-L-Carnitine. Drugs and Aging, 1998, 12, 0003-0249.	2.7	0
98	Response to Letter Regarding Article, "Acute Pharmacological Conversion of Atrial Fibrillation to Sinus Rhythm". Circulation, 2009, 119, .	1.6	0
99	Response by Hess and Hiatt to Letter Regarding Article, "A Structured Review of Antithrombotic Therapy in Peripheral Artery Disease With a Focus on Revascularization: A TASC (InterSociety) Tj ETQq1 1 0.784314 rrgBT /Overlock 10 2524-2525.	1.6	0
100	Impact of chronic kidney disease on hemoglobin among patients with peripheral artery disease treated with P2Y12 inhibitors: Insights from the EUCLID trial. Vascular Medicine, 2021, 26, 1358863X2110176.	1.5	0
101	Nonatherosclerotic limb ischemia: Prompt evaluation and diagnosis. Cleveland Clinic Journal of Medicine, 2016, 83, 741-751.	1.3	0
102	Abciximab added to urokinase increased amputation-free survival in peripheral arterial occlusion of the legs. ACP Journal Club, 2002, 137, 12.	0.1	0
103	Review: β -blockers do not reduce walking capacity or calf blood flow in peripheral arterial disease. ACP Journal Club, 1992, 116, 3.	0.1	0
104	Review: Magnetic resonance angiography detects lower-extremity arterial disease in claudication or critical limb ischemia. ACP Journal Club, 2001, 135, 109.	0.1	0